Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jun 15:5:49.
doi: 10.1186/1475-2875-5-49.

Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso

Sheick Oumar Coulibaly  1 , Désiré Nezien, Salifou Traoré, Bibiane Koné, Pascal Magnussen
Affiliations

Therapeutic efficacy of sulphadoxine-pyrimethamine and chloroquine for the treatment of uncomplicated malaria in pregnancy in Burkina Faso

Sheick Oumar Coulibaly et al. Malar J. .

Abstract

Background: A reduction in the therapeutic efficacy of chloroquine (CQ) and sulphadoxine-pyrimethamine (SP) has recently been observed in Burkina Faso. As these two drugs are used in pregnancy, their efficacy in pregnant women was studied to directly assess the level of drug resistance in this specific population, rather than to extrapolate results of studies conducted in children < 5 years of age.

Methods: During the malaria transmission season of 2003 in Ouagadougou, the clinical efficacy of SP and CQ, using the WHO 28-day protocol, was assessed in primigravidae and secundigravidae presenting with uncomplicated malaria.

Results: PCR-corrected results by day 28 showed that among 62 women treated with SP, eight (12.9%) experienced late parasitological failure, but no clinical failures. Among 60 women treated with CQ, the overall failure rate was 46.7% including 1.7% early treatment failures, 5% late clinical failures and 40% late parasitological failures. SP induced a haemoglobin gain of 0.3 g/dL by day 14 and 0.9 g/dL by day 28. Treatment responses were independent of gravidity, gestational age and prior antenatal care visits.

Conclusion: While CQ should no longer be used, the efficacy of SP is still compatible with use for intermittent preventive treatment (IPT) in pregnancy. However, given the possible spread of resistance, the drug should be restricted in its use.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trial profile. (*RHF: recent history of fever)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization . A Strategic Framework for Malaria Prevention and Control During Pregnancy in the African Region. Brazzaville: WHO Regional Office for Africa; 2004. AFR/MAL/04/01.
    1. Brabin BJ. An analysis of malaria in pregnancy in Africa. Bull World Health Organ. 1983;61:1005–1016. - PMC - PubMed
    1. Brabin BJ. Applied Field Research in Malaria reports, no 1. Geneva, Switzerland. World Health Organization; 1991. The risks and severity of malaria in pregnant women. (TDR/FIELDMAL/1)
    1. McGregor IA. Epidemiology of malaria and pregnancy. Am J Trop Med Hyg. 1984;33:517–525. - PubMed
    1. Mutabingwa TK. Malaria and pregnancy: epidemiology, pathophysiology and control options. Acta Trop. 1994;57:239–254. doi: 10.1016/0001-706X(94)90070-1. - DOI - PubMed

Publication types